Regulus Therapeutics

Graphic image of two hands shaking with employeesexecutives on the forearms of each shaking hand
Biotech

Novartis pays $800M to buy Regulus for phase 3-ready kidney drug

If approved, Regulus' farabursen will enter a market already served by Otsuka’s Jynarque.
Nick Paul Taylor Apr 30, 2025 9:30am
Max skydiving

Atai, Eli Lilly, Novartis & more—Chutes & Ladders

May 17, 2024 8:30am
graphic of a man with money identifying new ideas

The Time 100: Tech influenced VC firm closes first $100M fund

Oct 26, 2022 11:08am
stop shut down close end button

Sanofi walks away from Regulus' kidney disease therapy

Jul 18, 2022 2:40pm
Patients undergoing kidney dialysis must have their hydration level closely monitored a newly-developed portable sensor make

Regulus again reprioritizes in attempt to turn ship around

Oct 13, 2021 11:18am
Boehringer

Boehringer, Dicerna pen $201M pact to hit NASH with RNAi 

Nov 2, 2017 6:30am